Canada Markets closed

ProMIS Neurosciences, Inc. (PMN.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
7.44+0.59 (+8.61%)
At close: 03:27PM EDT
Full screen
Previous Close6.85
Open6.90
Bid7.15 x 0
Ask7.59 x 0
Day's Range6.90 - 7.44
52 Week Range6.00 - 12.22
Volume1,600
Avg. Volume3,547
Market Cap3.212B
Beta (5Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer

    New CEO brings 25 years’ experience and successful track record in neurological and neuropsychiatric drug developmentTORONTO, Ontario and CAMBRIDGE, Massachusetts , Sept. 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, announced today that it has appointed Gail

  • GlobeNewswire

    ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results

    TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 15, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three months ended June 30, 2022. “Q2 was another quarter of strong pro

  • GlobeNewswire

    ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference

    Poster presentation of study highlighting oligomer selectivity of PMN310 compared to that of other amyloid-beta-directed antibodiesTORONTO, Ontario and CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, today announced details of its poster pr